A higher expression of ZNF707 (median survival, 65.1 months vs. not reached; p < 0.001) or TNFRSF10B (64.9 months vs. 92.8 months, p < 0.001) and a lower expression of RHOBTB2 (71.8 months vs. not reached, p = 0.007) were significantly associated with decreased ccRCC patient overall survival. Here, ZNF707 is linked to nonpapillary renal cell carcinoma.